Facing increasing competition to PI3Kα inhibitor Piqray (alpelisib) in breast cancer, Novartis AG looks to bolster its pipeline with next-generation programs, including phase I/II-stage candidate SNV-4818, by way of a potential $3 billion deal with Synnovation Therapeutics LLC. Read More
Attacking attention deficit hyperactivity disorder (ADHD) from two different angles, thanks to a new asset just brought aboard, should help Collegium Pharmaceutical Inc. protect its revenue stream in the pesky and widespread condition. Stoughton, Mass.-based Collegium disclosed its pact March 19 with Corium Therapeutics Holdings LLC for the former to buy the latter’s Azstarys (serdexmethylphenidate and dexmethylphenidate). Read More
Australia is attempting a once-in-a-generation reset of its innovation system, and biotech industry leaders have lauded the federal government’s independent review into Australia's slipping R&D ranks and its proposals to reverse the decline. Read More
Scientists at Great Ormond Street Children’s Hospital in London have reported a new advance for tissue engineered grafts in a lab-grown esophagus that has sufficient muscle regeneration to coordinate peristalsis, enabling the recipient to swallow. The aim is to generate grafts that can be used to treat babies born with the rare congenital condition esophageal atresia, in which the esophagus fails to connect to the stomach, usually forming a close pouch instead. Read More
NIH Director Jay Bhattacharya is being fact-checked on his off-the cuff responses at a Senate Health, Education, Labor and Pensions Committee hearing in February. The fact-checkers are nine Democratic lawmakers from Massachusetts, only one of whom (Sen. Ed Markey) is on the committee and attended the hearing. In fact, seven of those signing the March 17 letter that questioned Bhattacharya’s veracity aren’t senators. They serve in the House. Read More
As the development of brain-computer interface (BCI) technologies gain momentum, Paradromics Inc. is building an ecosystem to enable collaboration between the company and academic researchers. Read More
Drug approvals by the U.S. FDA totaled 26 in the first two months of 2026, with eight approvals in January and 18 in February. Compared with 2025, when approvals reached 12 in January and 16 in February (28 total), early 2026 activity is consistent with historical ranges. Read More
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change how new drugs are developed to achieve more effective therapies. This new perspective could rethink strategies that depend not so much on the target itself, but on the precise moment at which it is addressed. Read More
A member of the CDC’s Advisory Committee on Immunization Practices (ACIP), physician and biochemist Robert Malone, who a judge earlier this week suggested lacked vaccine-related experience, wrote March 19 on X that the committee “has been disbanded.” Nearly six hours later, he followed up, saying it was a “miscommunication.” Read More
Imbiologics Corp.’s market capitalization reached ₩1.5 trillion (US$1.02 billion) on its Kosdaq debut March 20, as the biotech seeks to become a leading antibody drugmaker for autoimmune diseases. Read More
New hires and promotions in the biopharma and med-tech industries, including: Aditxt, Atossa, Boost, Clearnote, Convergent, Harbour, Secarna, Xenoco. Read More
Clinical updates for biopharma and med tech, including data readouts and publications: AC Immune, AL-S Pharma, C2N, Causeway, Clearmind, Kelun-Biotech, Pfizer, Totus, Vaxcyte. Read More
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Bayer, Conmed, Endevica, Eurosets, Formycon, GE, Gossamer, Illumina, Intelerad, Kalohexis, Klinge, Labcorp, Micro-Tech Endoscopy, Orion, Pharmability, Regeneron, Tirmed, Xcath. Read More
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Belief Biomed, Fluoguide, GSK, Livanova, Nia, Remix, Sarepta. Read More
